Gabelli Funds LLC Aurinia Pharmaceuticals Inc. Transaction History

Gabelli Funds LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 10, 2022	SELL	$6.66 - $12.39 $732,600 - $1.36 Million	-110,000 Reduced 28.21%	280,000 $2.11 Million
Q1 2022 May 13, 2022	BUY	$10.05 - $22.48 $301,500 - $674,400	30,000 Added 8.33%	390,000 $4.83 Million
Q4 2021 Feb 11, 2022	BUY	$17.78 - $33.08 $800,100 - $1.49 Million	45,000 Added 14.29%	360,000 $8.23 Million
Q3 2021 Nov 12, 2021	BUY	$10.93 - $23.55 $273,250 - $588,750	25,000 Added 8.62%	315,000 $6.97 Million
Q2 2021 Aug 13, 2021	BUY	$10.0 - $14.52 $550,000 - $798,600	55,000 Added 23.4%	290,000 $3.76 Million
Q1 2021 May 14, 2021	BUY	$12.3 - $18.73 $2.89 Million - $4.4 Million	235,000 New	235,000 $3.05 Million

191

56.2M

499K

637K

Ticker AUPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,892,000
Market Cap $1.03B
Description
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license...

Get notified when there are updates to the investment portfolio of Gabelli Funds LLC, based on Form 13F filings with the SEC.

Stay updated on Gabelli Funds LLC with notifications on news.